Core Viewpoint - The company has a designed production capacity of 8,000 tons per year for lithium hexafluorophosphate products and holds a leading market share in the active pharmaceutical ingredient metronidazole, with products sold to dozens of countries and regions globally, establishing strong partnerships with well-known pharmaceutical companies [1] Group 1 - The company has a designed production capacity of 8,000 tons per year for lithium hexafluorophosphate products [1] - The company holds a leading market share in metronidazole active pharmaceutical ingredients [1] - The company's products are sold to dozens of countries and regions globally [1] Group 2 - The company has established strong partnerships with well-known pharmaceutical companies [1]

Group 1 - The company, Hongyuan Pharmaceutical (301246), responded to investor inquiries on November 19, indicating that details regarding product production and planning should be monitored through the company's information disclosures [1]

Core Points - The company announced the construction project of the Wuxue Hongyuan plant, which includes public utilities and auxiliary production facilities [1] - The budget for the Wuxue Hongyuan plant supporting project is 138 million yuan, with actual investment reaching the same amount by the mid-2025 report, indicating a project progress of 99.95% [3] - The expected completion date for the project is September 18, 2025 [3] Summary by Categories - **Project Details** - The main construction content of the Wuxue Hongyuan plant supporting project includes public utilities and auxiliary production facilities [1] - **Financials** - The project has a budget of 138 million yuan, with actual expenditures matching this budget as of the mid-2025 report [3] - **Progress and Timeline** - The project is nearly complete, with a progress rate of 99.95%, and is expected to be finished by September 18, 2025 [3]

Core Viewpoint - Hongyuan Pharmaceutical provided insights into its procurement of production raw materials, emphasizing the importance of various factors in the purchasing process [1] Group 1: Raw Materials - The main raw materials required by the company include ethylene glycol, ethylene oxide, acetaldehyde, nitric acid, ammonia water, lithium fluoride, and methyl cyanoacetate [1] - Most of these materials are basic chemical products, with a large number of companies in the industry and relatively mature processes [1] Group 2: Procurement Considerations - When procuring raw materials, the company considers multiple factors such as price, quality, timeliness of supply, stability, payment terms, and transportation [1] - Detailed information regarding the procurement prices of major raw materials from 2019 to 2021 can be found in the company's prospectus, specifically in Section 6 "Business and Technology" and Chapter 5 "Purchasing Situation of the Issuer" [1]

Core Viewpoint - The company is enhancing its lithium battery segment by integrating electrolyte additives and functional lithium salts with its lithium hexafluorophosphate business, aiming to improve business scale and market competitiveness [1] Group 1 - The company is actively engaging with investors through interactive platforms to provide updates on its strategic initiatives [1] - The focus on electrolyte additives and functional lithium salts indicates a strategic move to diversify and strengthen its product offerings in the lithium battery market [1] - The integration of these products with the existing lithium hexafluorophosphate business is expected to create synergies that will benefit the overall business performance [1]

证券日报网讯宏源药业11月14日在互动平台回答投资者提问时表示，公司产品成本受多种因素影响，具 体营业收入、营业成本、营业利润情况，请关注公司定期报告。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article highlights that the upgrade rate of stocks with consecutive gains exceeds 50%, indicating strong market interest and activity in certain sectors [1] - A total of 70 stocks hit the daily limit up, with 21 stocks classified as consecutive gainers, including 10 stocks with three or more consecutive gains [1] - The upgrade rate for consecutive gainers is reported at 55.56%, excluding ST and delisted stocks, reflecting a robust performance in the market [1] Group 2 - The article notes that local stocks related to map speculation are performing well, with Pingtan Development achieving 13 consecutive gains in 21 days, Sanmu Group with 7 gains in 10 days, and Dongbai Group with 6 gains in 8 days [1] - Defensive sectors such as coal, gas, and electricity have seen a rise due to cold weather news, with Antai Group achieving 13 gains in 22 days and Daya Energy with 2 gains in 4 days [1] - The lithium battery sector experienced a split after a previous surge, with companies like Furui Shares achieving 7 consecutive gains and Shida Shenghua with 3 consecutive gains, while others like Aoke Shares and Tianhong Lithium fell over 9% [1]

宏源药业于2023年3月20日在深交所创业板上市，公开发行股票4,725.72万股，发行价格为50.00元/ 股，保荐机构（主承销商）为民生证券股份有限公司（现为国联民生证券股份有限公司），保荐代表人 为谢广化、肖继明。 中国经济网北京11月14日讯 宏源药业(301246.SZ)今日收报20.82元，跌幅7.05%。该股目前处于破 发状态。 上市首日，宏源药业盘中创下股价高点45元，此后股价震荡下跌。 宏源药业首次公开发行股票募集资金总额为人民币236,286.00万元，扣除发行费用后募集资金净额 为219,584.37万元。该公司最终募集资金净额比原计划多154,511.37万元。宏源药业于2023年3月14日披 露的招股说明书显示，该公司拟募集资金65,073.00万元，用于研发中心及多功能试验车间项目、抗病毒 原料药及中间体项目、年产25亿片（粒）高端制剂车间项目。 宏源药业首次公开发行股票的发行费用总额为16,701.63万元，其中保荐及承销费用13,931.96万元。 （责任编辑：何潇） ...

Core Viewpoint - Hongyuan Pharmaceutical (301246.SZ) is strategically expanding its product offerings to include electrolyte additives and functional lithium salts, which will synergize with its lithium hexafluorophosphate business, thereby enhancing the scale and market competitiveness of its lithium battery segment [1]. Group 1 - The company is focusing on the development of electrolyte additives and functional lithium salts [1]. - This expansion is aimed at creating industrial synergy with its existing lithium hexafluorophosphate business [1]. - The initiative is expected to continuously improve the business scale and market competitiveness of the company's lithium battery sector [1].

（编辑 王雪儿） 证券日报网讯 宏源药业11月13日在互动平台回答投资者提问时表示，公司六氟磷酸锂是电解液的主要 材料，下游客户是电解液厂家。公司高度重视客户关系维护，并注重保护客户隐私，具体情况请关注公 司的信息披露。 ...